Ab­b­Vie’s can­cer drug fails Phase 3 com­bo study to treat oth­er bone mar­row dis­eases

Ab­b­Vie said Ven­clex­ta did not im­prove sur­vival in pa­tients with myelodys­plas­tic syn­dromes when com­bined with an­oth­er com­mon­ly pre­scribed drug.

The drug­mak­er

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER